Clinical Trial Search

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Conversion Rate of Inoperable to Operable

Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…

Primary: Number of Participants With Progressive Disease, — 2 Participants

Primary: Overall Survival — 24.8 Months

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Overall Survival (OS) — 9.38; 14.7 Months

Primary: Median Overall Survival (OS) — 42 months

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants

Primary: Tarceva Maximum Tolerated Dose in mg — 150 mg

Primary: One Year Survival Rate — 0.502 proportion of patients

Primary: Progression-free Survival — 5.7 months

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: CD8+ T Cell Density in Tumor Tissue — 5.4 log (cells per mm^2)

Primary: Study Drug-related Adverse Events — 3; 6; 3; 5 Participants

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity — 1; 5 Participants

Primary: MK-0646 Maximum Tolerable Dose — 0; 0; 0; 2 participants

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)

Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months

Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026

Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.